Reduction in the activity of cathepsins using the pharmacologic inhibitor JPM, or deficiency of CatS, impaired angiogenic switch in progenitor lesions, affecting angiogenesis, tumor growth, vascularity, and invasiveness [12], [13]. The gene discussed is CTSS; the disease is neoplasm.